RxDoctor Payments Data

Kellie Atlas

Nurse Practitioner · Paterson, NJNPI 1972834703

Payments from drug & device makers

$5,459in general payments, 2019–2025

Across 205 payments — averaging $26.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$3K
  • Viiv Healthcare Company$2K
  • Merck$174
  • GSK$110
  • Johnson & Johnson$65
  • Novo Nordisk$15

What the payments were for

  • Food & beverage$5,459100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead98$3,491
Viiv Healthcare Company92$1,603
Merck9$174
GSK1$110
Johnson & Johnson4$65
Novo Nordisk1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,459 in reported general payments places this provider in the 95th percentile of 2,138 nurse practitioner providers in New Jersey.

See all nurse practitioner providers in New Jersey

Medicare billing

Part B allowed, 2024
$3,169
Medicare patients
22
Services billed
49

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OdefseyEmtricitab/Rilpiviri/Tenof Ala144$546,921
BiktarvyBictegrav/Emtricit/Tenofov Ala50$224,106
JulucaDolutegravir/Rilpivirine59$206,482
GenvoyaElviteg/Cob/Emtri/Tenof Alafen30$138,769
DovatoDolutegravir Sodium/Lamivudine37$108,362
TivicayDolutegravir Sodium45$99,898
TriumeqAbacavir/Dolutegravir/Lamivudi20$61,998
PrezcobixDarunavir/Cobicistat26$61,482
DescovyEmtricitabine/Tenofov Alafenam14$30,748
PifeltroDoravirine17$29,437
Isentress HdRaltegravir Potassium11$21,857
Janumet XrSitagliptin Phos/Metformin Hcl17$12,062
RybelsusSemaglutide11$10,536
LinzessLinaclotide15$9,633
Atovaquone13$4,218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyJuluca, Dovato, Tivicay, Triumeq$1,603$476,740161 claims
GileadBiktarvy, Genvoya, Descovy$3,491$393,62394 claims
MerckPifeltro, Isentress Hd, Janumet Xr$174$63,35645 claims
Johnson & JohnsonPrezcobix$65$61,48226 claims
Novo NordiskRybelsus$15$10,53611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,138 nurse practitioner providers in New Jersey.

Other nurse practitioner in Paterson

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →